Alzheimer’s Multiclassification Using Explainable AI Techniques
In this study, we address the early detection challenges of Alzheimer’s disease (AD) using explainable artificial intelligence (XAI) techniques. AD, characterized by amyloid plaques and tau tangles, leads to cognitive decline and remains hard to diagnose due to genetic and environmental factors. Utilizing deep learning models, we analyzed brain MRI scans from the ADNI database, categorizing them into normal cognition (NC), mild cognitive impairment (MCI), and AD. The ResNet-50 architecture was employed, enhanced by a channel-wise attention mechanism to improve feature extraction. To ensure model transparency, we integrated local interpretable model-agnostic explanations (LIMEs) and gradient-weighted class activation mapping (Grad-CAM), highlighting significant image regions contributing to predictions. Our model achieved 85% accuracy, effectively distinguishing between the classes. The LIME and Grad-CAM visualizations provided insights into the model’s decision-making process, particularly emphasizing changes near the hippocampus for MCI. These XAI methods enhance the interpretability of AI-driven AD diagnosis, fostering trust and aiding clinical decision-making. Our approach demonstrates the potential of combining deep learning with XAI for reliable and transparent medical applications.
Authors
- Tagne Poupi Theodore Armand (ORCID: https://orcid.org/0000-0002-5933-3163)
- Kouayep Sonia Carole
- Kamese Jordan (ORCID: https://orcid.org/0009-0000-1929-2638)
- The Alzheimer’s Disease Neuroimaging Initiative The Alzheimer’s Disease Neuroimaging Initiative
- Hee-Cheol Kim
Institutions
- Inje University (KR)
Publication Details
- Journal
- Applied Sciences
- Published
- 2024-09-14
- DOI
- https://doi.org/10.3390/app14188287
- Citations
- 6
- Primary Topic
- Explainable Artificial Intelligence (XAI)
- Type
- article
- Field-Weighted Citation Impact
- 2.08
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Eisai
- Iran Telecommunication Research Center
- Servier
- H. Lundbeck A/S
- Ministry of Science and ICT, South Korea
- National Institutes of Health
- Canadian Institutes of Health Research
- Institute for Information and Communications Technology Promotion